Cn / En

CM05369


CM05369

Key word结直肠癌, PDX, 体内药效,体外药效,免疫系统人源化,5-FU, DM1, DS8201, DXD, SN38, TAS-102, 奥沙利铂, 奥希替尼, 多西他赛, 恩考拉非尼, 吉西他滨, 拉帕替尼, 雷替曲塞, 芦康莎妥珠单抗, 曲美替尼, 顺铂, 丝裂霉素C, 依维莫司, 长春新碱, 紫杉醇,

Model Information

Model IDCM05369
Cancer Type结直肠癌(肝转移)
Cell Subtype腺癌
Differentiation中分化
Collection Site肝
Metastatic Site肝转移
GradeII
TNM stagingypT3N0M1a
IHC diagnosisEGFR(3+),HER2(0),KI67(+80%),MLH1(+),MSH2(+),MSH6(+),PMS2(+)。Cmet(2+),EGFR(-),HER2(2+),KI67(90%),MLH1(+),MSH2(+),MSH6(+),PMS2(+),AFP(-),Hep(+),SALL4(-)。
Pathology diagnosis

临床诊断:直乙交界中低分化腺癌同时性肝转诊断意见

1.(肝方叶部分):

肝组织中可见中分化腺癌,结合临床,符合肠肝转移,大小2.0×1.5×1.5cm;

癌细胞坏死率约30%;

癌延伸至肝灼烧缘;

2.(肝S4部分)

肝组织中可见中分化腺癌,结合临床,符合肠癌肝转移,直径0.7cm;

癌细胞坏死不明显(坏死率<10%);

切缘未见癌;

3.(疤痕组织)

送检皮肤及皮下脂肪组织,真皮内纤维组织增生,符合瘢痕,未见癌;

4.(门静脉旁淋巴结)

淋巴结未见癌转移(0/3)

EGFR(3+),HER2(0),KI

Clinical Treatment Records 

Model Data

Histopathological Images

 

Tumor growth curve

  

In vivo efficacy of SOCs

  
  
  
  

In vitro efficacy of SOCs

药物名称靶点药物说明药效细胞活率(%)
LucatumumabMechanism of action: Trop-2-targeted ADC with a topoisomerase I inhibitor SN-38 payload    Target: Trop-2 (trophoblast cell-surface antigen 2)Indications: Triple-negative breast cancer, HR+/HER2− breast cancer, urothelial carcinoma    Clinical application: Second-line and subsequent therapy, later-line therapy after platinum-based chemotherapy and immunotherapy 17.07
SN38Mechanism of action: Topoisomerase I inhibitor (active metabolite of irinotecan)    Target: Topoisomerase IIndications: Colorectal cancer, small cell lung cancer, pancreatic cancer, etc.    Clinical application: First-/second-line therapy (as a component of irinotecan) 30.7027
DXDMechanism of action: Topoisomerase I inhibitor    Target: Topoisomerase IIndications: As a payload of ADC drugs (e.g., DS8201)    Clinical application: Administered via ADC 45.1891
DS8201Mechanism of action: HER2-targeted antibody-drug conjugate (ADC) containing a topoisomerase I inhibitor    Target: HER2 receptorIndications: HER2-positive breast cancer, gastric cancer, non-small cell lung cancer (HER2-mutated)    Clinical application: Second-line and subsequent therapy (breast cancer), later-line therapy (other tumors) 45.862
TrametinibMechanism of action: MEK1/2 inhibitor    Target: MEK1/2Indications: BRAF V600-mutated melanoma, non-small cell lung cancer    Clinical application: First-line combination with dabrafenib (melanoma) 49.6177
Mitomycin CMechanism of action: Alkylating agent, induces DNA cross-linking    Target: DNAIndications: Gastric cancer, pancreatic cancer, bladder cancer (intravesical instillation), head and neck cancer    Clinical application: Second-line and subsequent therapy 57.9245
OxaliplatinMechanism of action: Platinum compound, forms DNA adducts    Target: DNAIndications: Colorectal cancer, gastric cancer, pancreatic cancer, esophageal cancer    Clinical application: First-line combination chemotherapy (e.g., FOLFOX) 59.1221
5-FUMechanism of action: Thymidylate synthase inhibitor, interferes with DNA synthesis    Target: Thymidylate synthase (TS)Indications: Colorectal cancer, gastric cancer, breast cancer, head and neck cancer, pancreatic cancer, etc.    Clinical application: First-/second-line foundational drug for combination chemotherapy 73.1878
OsimertinibMechanism of action: Third-generation EGFR-TKI, irreversible inhibitor    Target: EGFR (including T790M mutation)Indications: EGFR-mutated non-small cell lung cancer    Clinical application: First-line therapy, second-line therapy for T790M-positive patients 74.2445
PaclitaxelMechanism of action: Microtubule-stabilizing agent, antimitotic    Target: TubulinIndications: Ovarian cancer, breast cancer, non-small cell lung cancer, pancreatic cancer, Kaposi's sarcoma    Clinical application: First-/second-line therapy 75.712
DocetaxelMechanism of action: Microtubule-stabilizing agent, antimitotic    Target: TubulinIndications: Breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, head and neck cancer    Clinical application: First-/second-line therapy 79.256
EncorafenibMechanism of action: BRAF inhibitor    Target: BRAF V600E/KIndications: BRAF V600-mutated melanoma, colorectal cancer    Clinical application: First-line combination with binimetinib (melanoma) 80.0711
DM1Mechanism of action: Tubulin inhibitor, antimitotic    Target: TubulinIndications: HER2-positive breast cancer (as a component of ADC drugs)    Clinical application: Second-line and subsequent therapy (administered via ADC) 82.1655
CisplatinMechanism of action: Platinum compound, induces DNA cross-linking    Target: DNAIndications: Testicular cancer, ovarian cancer, bladder cancer, head and neck cancer, lung cancer, etc.    Clinical application: Cornerstone drug of first-line chemotherapy 82.5046
VincristineMechanism of action: Vinca alkaloid, tubulin inhibitor    Target: TubulinIndications: Lymphoma, leukemia, multiple myeloma, pediatric tumors    Clinical application: First-line combination chemotherapy 82.9262
LapatinibMechanism of action: Dual HER2/EGFR tyrosine kinase inhibitor (TKI)    Target: HER2, EGFRIndications: HER2-positive breast cancer (combined with capecitabine)    Clinical application: Second-line and subsequent therapy 85.4335
RaltitrexedMechanism of action: Thymidylate synthase inhibitor    Target: Thymidylate synthase (TS)Indications: Colorectal cancer (patients intolerant to 5-FU)    Clinical application: Second-line and subsequent therapy 86.9926
GemcitabineMechanism of action: Nucleoside analog, inhibits DNA synthesis    Target: Ribonucleotide reductase, DNA polymeraseIndications: Pancreatic cancer, non-small cell lung cancer, breast cancer, bladder cancer, ovarian cancer    Clinical application: First-line therapy (pancreatic cancer), first-/second-line therapy (other tumors) 88.7893
EverolimusMechanism of action: mTOR inhibitor    Target: mTORIndications: Renal cell carcinoma, neuroendocrine tumors, HR-positive breast cancer, SEGA    Clinical application: Second-line and subsequent therapy 90.1759
TAS-102Mechanism of action: Thymidine analog plus thymidine phosphorylase inhibitor    Target: DNA synthesis + thymidine phosphorylase inhibitionIndications: Metastatic colorectal cancer, gastric cancer    Clinical application: Third-line and subsequent therapy 96.2861

药效图例:

绿色 = 低细胞活率,药效显著

红色 = 高细胞活率,耐药